Company founder, trustee and share-holder. Dr. Yu is an expert in signal transduction and cancer biology. Dr. Yu also holds joint appointment as an adjunct Associate Professor of Boston University Medical School, a Professor at the Shanghai Institute of Materia Medica, a visiting Professor at the Shanghai Institute of Organic Chemistry, the Institute of Medical Sciences of China, the Union Medical University of China, Fudan University, and the Xian 4th Military Medical University. Dr. Yu is a member and a Secretary on the Board of the Association of US-China Biomedical Sciences and the Board of the Association of the US-China Pharmaceutical Development. Dr. Yu obtained his BS in Biochemistry from Fudan University in 1982. He was in the first class of the CUSBMBEA program. Dr. Yu obtained his Ph.D. in Molecular Biology and Biochemistry in 1988 from Brandeis University at Boston, Massachusetts, USA. From 1988 to 1991, he did his postdoctoral training in cancer biology in Dr. Robert Weinberg’s laboratory at MIT. He was appointed as an Assistant Professor in 1991 and subsequently an Associate Professor at the Boston University Medical School. In 2002, Dr. Yu returned to China and founded the Shanghai Ambrosia Pharmaceuticals, Ltd. Dr. Yu is an expert in the areas of molecular and cellular biology of cancer and signal transduction. He has published more than 40 articles in the first class journals including Nature and Science. He is experienced in designing and carrying out drug screens based on the modern biology concepts. His wide expertise in molecular, cellular and behavior sciences and his leadership is critical for achieving the goals of the company

Company founder and chief scientist. Dr. Yuan is a full Professor at Harvard Medical School and a member of the American Academy of Arts and Sciences. Dr. Yuan is a recognized leading expert in the field of cell death, an area of research critical for many diseases including cancer, inflammation and neuro-degeneration which are the targeting diseases of the company. Dr. Yuan is also an Honorary Professor at the Shanghai Institute of Organic Chemistry and Shanghai Institute of Materia Medica. In 1977, Dr. Yuan scored the No 1 in the College Entrance Exam in Shanghai among more than 100,000 high school graduates. Dr. Yuan obtained her BS in Biochemistry from Fudan University in 1982. At the same year, she took part in the CUSBMBEA program and become a graduate student the Neuroscience Program at Harvard Medical School. She obtained Ph.D. in Neuroscience from Harvard University in 1989. Dr. Yuan joined the faculty of Harvard Medical School in 1993 and became a full Professor in 2000. Dr. Yuan is a founding member for the field of apoptosis. Her work revealed the first molecular mechanism in regulating of mammalian apoptosis. She has published more than 80 articles in leading journals such as Cell, Science and Nature. Her works received more than 12,000 citations in the PubMed. She was invited by the Nobel Committee multiple times to give seminars. Her works as a student made important contributions for the 2002 Nobel prize of Dr. H.R. Horvitz who was her Ph.D. advisor. Dr. Yuan is a Senior Editor of Journal of Cell Biology. She was frequently consulted by many major pharmaceutical companies such as Bristol-Meyers Squibb, Pfizer, GlaxoSmithKline, Aventis, Merck, Millennium, Amgen and Biogen, etc.

founding member, trustee, share-holder and scientist. Dr. Liu is a world’s leading expert in chemical biology and pharmacology. Dr. Liu is a full Professor at Johns Hopkins University and a visiting Professor at the Shanghai Institute of Organic Chemistry and Shanghai Institute of Materia Medica. He obtained his BS from Nanjing University in 1983 and Ph.D. in biology from MIT in 1990. He was a faculty of Department of Biology at MIT before joining Johns Hopkins. He published more than 50 articles in the first class journals such as Cell, Science and Nature. Dr. Liu is an expert in high throughput drug screens and target identification. His expertise is critical for designing high throughput screen platforms.